Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Cameron Winklevoss Critiques SEC's Bitcoin ETF Policy
-
United States Cellular Corp. Plunges On Reporting Quarterly Loss, Missing Street View
-
Cryptos Muted Amidst A Mixed Global Inflation Picture
-
With Bitcoin Above $31,000 Milestone, MicroStrategy’s BTC Stash Is Back In The Green
-
If Bitcoin Is So Valuable, Why Is It Down So Much This Year?